@entity2124 -releasing peptide-6 stimulates sleep, XXXX , ACTH and @entity701 release in normal @entity1 .

@entity1 @entity7704 @entity2124 @entity701 @entity14950 @entity25
The synthetic hexapeptide @entity2124 -releasing peptide ( @entity14950 -6) stimulates @entity2124 ( @entity2124 ) release in animals and @entity1 . @entity7704 ( @entity7704 ) has the same effect. In addition, pulsatile administration of @entity7704 in normal @entity1 results in @entity25 ( @entity25 ) and blunted @entity701 levels. The effect of @entity14950 on nocturnal hormone secretion and on the sleep electroencephalogram (EEG) is still unknown. We compared the effect of repetitive i.v. boluses (4 x 50 micrograms) of @entity14950 and placebo (PL) on the sleep EEG (23.00 to 07.00 h) and on the secretion profiles of @entity2124 , ACTH and @entity701 (20.00 to 07.00 h) in normal male controls. After @entity14950 , the @entity2124 concentration (22.00 to 03.00 h) increased (15.4 +/- 9.6 ng/ml after @entity14950 vs. 5.5 +/- 4.0 ng/ml after PL, p < 0.02), as did the ACTH level (22.00 to 02.00 h: 21.0 +/- 5.3 pg/ml after @entity14950 vs. 16.6 +/- 3.1 pg/ml after PL, p < 0.02). During the total night, and particularly during the first half of the night, @entity701 secretion was enhanced (22.00 to 03.00 h: 56.0 +/- 31.0 ng/ml after @entity14950 vs. 25.2 +/- 9.0 ng/ml after PL, p < 0.02). Stage 2 sleep increased (270.1 +/- 25.3 min after @entity14950 vs. 245.4 +/- 25.8 min after PL, p < 0.02), whereas other sleep-EEG variables including @entity25 remained unchanged. Our data demonstrate that @entity14950 stimulates not only @entity2124 release but also hypothalamic-pituitary-adrenocortical hormone secretion. The latter effect is opposite to the blunting of @entity701 after @entity7704 . Both @entity14950 and @entity7704 promote sleep. However, @entity14950 enhances stage 2 sleep and does not affect @entity25 .(ABSTRACT TRUNCATED AT 250 WORDS)
